Sanjay Lakhotia

Chief Business Officer at Zenith Epigenetics

Dr. Lakhotia serves as the Chief Business Officer and heads the development function at Zenith. Sanjay has been instrumental in recent collaborations and partnerships for Zenith – including Pfizer, NCI, UCSF, Merck, and Newsoara – which have helped to significantly advance and expand the clinical pipeline of ZEN-3694 in various cancer indications. He has also led Zenith’s programs from Investigational New Drug filings to mid-stage clinical trials.

Sanjay brings over 25 years of experience in corporate development, product development, and strategy at leading biotechnology and pharmaceutical companies. Between 2010 and 2013, he led corporate development at Pathway Therapeutics, clinical-stage cancer, and autoimmune company. Prior to Pathway, Sanjay was Senior Director of Corporate Development at Portola Pharmaceuticals, where his responsibilities included product licensing and program leadership. While at Portola, he contributed to the partnering of a significant Phase 2 asset and championed the development of an important cardiovascular drug now marketed in North America.


Org chart